J&J Pharma Revenues up 3% in the Quarter

Johnson & Johnson
3Q Revenue: $23.8 billion (+2%)
3Q Earnings: $4.5 billion (+22%)
YTD Revenue: $71.2 billion (+3%)
YTD Earnings: $14.4 billion (-11%)
Comments: Pharmaceutical sales were up 3% to $13.3 billion, driven by DARZALEX (daratumumab), a biologic for the treatment of multiple myeloma, TREMFYA (guselkumab), a biologic for the treatment of moderate to severe plaque psoriasis, and active psoriatic arthritis, STELARA (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases, ERLEADA (apalutamide), a next-gen androgen receptor inhibitor for the treatment of prostate cancer, and INVEGA SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia. The Janssen COVID-19 Vaccine (Ad26.COV2.S) sales were $489 million in the quarter, down 3%. Growth in the quarter was partially offset by declines in sales of REMICADE (infliximab), a biologic for the treatment of several immune-mediated inflammatory diseases and IMBRUVICA (ibrutinib), an oral, once daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer.